The goal of this pilot RCT is to investigate the acceptability and feasibility of an unguided culturally adapted self-help app for grieving Syrian refugees in Switzerland. Furthermore, the study will examine whether using the app has an effect on secondary outcomes (e.g., grief symptoms).The main questions it aims to answer are:
* Is the self-help app culturally acceptable and feasible in this target group and what do we need to adapt?
* Does the use of the self-help app reduce grief symptoms? (amongst other secondary outcomes)
Participants will be asked to:
* Complete a baseline assessment
* then use the self-help app for 5 weeks
* Complete a second assessment and participate in a short semi-structured interview regarding acceptability and feasibility.
Researchers will compare an intervention group to a wait-list control group to see if the use of the self-help app has an effect on secondary outcomes.

开始日期2024-01-29

申办/合作机构

University of Zurich

[+1]

NCT04020224 / WithdrawnN/AIIT

A Randomized, Controlled, Phase I Clinical Trial to Assess the Safety of Whole Blood Treated With Amustaline (S-303) and Glutathione (GSH), a Pathogen Reduction System, in Anemic Patients

The pathogen reduction system for whole blood using amustaline (S-303) and glutathione (GSH) hast a potential to decrease transfusion-transmitted infection. There is a scientific basis to hypothesize, that cells containing DNA and RNA such as bacteria, viruses and parasites that could be present in blood collected from asymptomatic infected donors are inactivated in the treated whole blood and therefore reduce the risk of transfusion-transmitted infections.
The aim of the study is to assess the safety of whole blood treated with amustaline and glutathione and transfused in patients with anemia.
This is a first-in-human-subjects study. Whole blood (WB) products treated with the amustaline (S-303) and glutathione (GSH) pathogen reduction technology have not been evaluated in human beings. However, red blood cells concentrates treated with amustaline and GSH have been evaluated in multiple clinical studies.
The study described in this protocol is a randomized, controlled, open-label Phase I clinical trial.
20 patients will be randomized into either the Test or Control arm in a ratio of 1:1.
10 patients assigned to the Test arm will receive one amustaline/GSH treated whole blood product.
10 patients assigned to the Control arm will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product.

开始日期2024-01-01

申办/合作机构

Swiss Transfusion SRC

[+1]

NCT05651737 / CompletedN/AIIT

Efficacy of an Unguided or Peer-guided App-based Psychosocial Intervention to Enhance Quality of Life in Arabic-speaking Refugees Residing in Switzerland: A Randomized Controlled Trial

The ongoing warfare and economic instability in the Middle East and in North Africa causes many people to leave their home countries. Arrived in a host countries, in this example, in Switzerland, they face a lot of structural and psychosocial hurdles. Particularly in the first years, building up a certain quality of life is complicated and challenging. To support this process, the Swiss Red Cross and the University of Bern have developed the Sui app. It contains structural and social information as well as low-intensity psychological tools to provide support to the everyday life of Arabic-speaking people in Switzerland.

开始日期2022-10-21

申办/合作机构

University of Bern

[+2]

100 项与 Swiss Transfusion SRC 相关的临床结果

登录后查看更多信息

0 项与 Swiss Transfusion SRC 相关的专利（医药）

登录后查看更多信息

项与 Swiss Transfusion SRC 相关的文献（医药）

2022-03-01·Bone Marrow Transplantation3区 · 医学

Audit of donor centre: guidelines by the World Marrow Donor Association Quality and Regulation Working Group

3区 · 医学

Article

作者: Schwarz, Carolin ; Haun, Sherry ; Wuchter, Jennifer ; Sengomona, Hirasine ; Ahmed, Salmah Mahmood ; Sacchi, Nicoletta ; Weber, Maren ; Tistl, Ingrid ; Kürsteiner, Oliver ; Thompson, Stephanie

AbstractAccording to the Standards of the World Marrow Donor Association (WMDA) 2020 [1] unrelated stem cell donor registries are responsible for compliance of their donor centres with these Standards. To ensure high stem cell product quality and high standards for safety and satisfaction of voluntary unrelated stem cell donors, we present here guidelines for audits of donor centres (DC) that can be used by new and established donor registries. They have been developed for registries relying on independent national or international DCs for the recruitment and management of Unrelated Donors (UD) for verification typing (VT)/extended tying (ET), work up processes and Hemopoietic Progenitor Cell (HPC) donation. The main goal of these guidelines is to support registries in verifying and auditing their affiliated DCs to ensure they are compliant with the WMDA Standards, as well as WMDA recommendations. We define the general requirements and recommendations for collaboration with the DC and guidelines to manage the UD, step by step from recruitment to follow-up. We also provide a checklist, intended to serve as a resource for auditors performing an audit at a DC.

2011-12-30·The Open Tissue Engineering and Regenerative Medicine Journal

Mesenchymal Stem Cells Derived from Wharton's Jelly and their Potential for Cardio-Vascular Tissue Engineering

作者: Semenov, O. V. ; Breymann, C.

A review.Exptl. results accumulated during last decade suggest that human perinatal tissues such as placenta, fetal membranes, and umbilical cord, as well as perinatal fluids such as, amniotic fluid and umbilical cord blood, harbor different amounts of multipotent precursor cells, called extra-embryonic mesenchymal stem cells (EE-MSCs).Perinatal EE-MSCs represent an intermediate cell type between pluripotent embryonic stem cells (ESCs) and multipotent MSCs derived from variety of postnatal human tissues, such as bone marrow, fat, dental pulp, etc.Multipotent mesenchymal cells obtained from connective Wharton's jelly tissue of umbilical cord (WJ-MSCs) currently emerged as particularly interesting type of perinatal EE-MSCs, related for therapeutical applications and cryobanking.These cells are easily assessable for isolation, possess fetal karyotype, and hold very active growth potential.Due to their unique developmental position WJ-MSCs exhibit specific phenotype which combines some markers expressed by postnatal bone marrowderived MSCs, such as CD73, CD90, and CD105 with some markers typically expressed by ESCs, such as Oct-3/4, Sox-2, and Nanog.In terms of plasticity WJ-MSCs demonstrate the potential for differentiation towards mesodermal and ectodermal lineages in vitro and in vivo.Addnl., extraembryonic tissues are normally discarded after birth and the isolation of WJ-MSCs is free of ethical concerns.In this work we aim to review previously obtained exptl. results, discuss different aspects concerning plasticity and immunomodulatory characteristics of WJ-MSCs, and evaluate the potential of these cells for biomedical and clin. applications.

Do Quantitative Levels of Anti-Spike-IgG Antibodies Aid in Predicting Protection from SARS-CoV-2 Infection? Results from a Longitudinal Study in a Police Cohort

作者: Endimiani, Andrea ; Branca, Mattia ; Blum, Manuel Raphael ; Baldan, Rossella ; Güntensperger, Dominik ; Tande, Aaron J ; Theel, Elitza S. ; Thierstein, Marc ; Berbari, Elie ; Büchi, Annina Elisabeth ; Widmer, Nadja ; Heg, Dik ; Niederhauser, Christoph ; Sendi, Parham ; Gowland, Peter ; Tinguely, Caroline

Objectives In a COVID-19 sero-surveillance cohort study with predominantly healthy and vaccinated individuals, the objectives were (i) to investigate longitudinally the factors associated with the quantitative dynamics of anti-spike IgG antibody levels, (ii) to evaluate whether the antibody levels were associated with protection from SARS-CoV-2 infection and (iii) to assess whether the association was different in the pre-Omicron compared with the Omicron period. Methods The QuantiVac Euroimmun ELISA test was used to quantify anti-S1 IgG levels. The entire study period (16 months), the 11-month pre-Omicron period and the cross-sectional analysis prior to the Omicron surge included 3219, 2310 and 895 reactive serum samples from 949, 919 and 895 study participants, respectively. Mixed-effect linear, mixed-effect time-to-event and logistic regression models were used to achieve the objectives. Results Age and time since infection or vaccination were the only factors associated with a decline of anti-S1 IgG levels. Antibody levels were significantly associated with protection from SARS-CoV-2 infection, and the association was higher for the Omicron than for the Alpha and Delta variants. In a prediction model, it was estimated that >8000 BAU/mL anti-S1 IgG was required to reduce the risk of infection with Omicron variants by 20% to 30% for 90 days. Conclusions Anti-S1 IgG antibody levels are associated with protection from infection. The levels in the pre-Omicron periods were less significant than during the Omicron surge, which in turn required very high levels for protection in a statistical model.

项与 Swiss Transfusion SRC 相关的新闻（医药）

2021-08-05

·GlobeNewswire

Global Stem Cell Banking Market to Reach US$11.3 Billion

New York, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Banking Industry" - 1 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is projected to grow at a 7.4% CAGR to reach US$7.3 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adipose Tissue-Derived Stem Cells (ADSCS) segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 6.6% share of the global Stem Cell Banking market. The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 6.4% CAGR for the Period of 2020-2027 The Stem Cell Banking market in the U.S. is estimated at US$2.1 Billion in the year 2020. The country currently accounts for a 29.55% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$2 Billion in the year 2027 trailing a CAGR of 6.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the year 2027. Bone Marrow-Derived Stem Cells (BMSCS) Segment Corners a 10.3% Share in 2020 In the global Bone Marrow-Derived Stem Cells (BMSCS) segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$592.8 Million in the year 2020 will reach a projected size of US$858.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027. Select Competitors (Total 78 Featured) Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Stem Cells, Application Areas, and the Different Types - A Prelude Applications of Stem Cells Types of Stem Cells Cord Blood Umbilical Cord Tissue Bone Marrow Stem Cells Adipose-Derived Stem Cells (ADSCs) Number of Clinical Trials Using Adipose Stem Cells: 2007-2018 Number of Adipose Stem Cell Trials by Phase: 2007 to 2018 Human Embryo-Derived Stem Cells (HESCS) Global Stem Cell Banking Market Poised for a Rapid Growth Developed Regions Lead, Emerging Economies to Spearhead Future Growth List of Family Cord Blood Banks in the US Placental and Cord Blood Banks Dominate the Cord Blood Banking Market Global Number of Annual Newborns and Private Cord Blood Banks Global Select Leading Cord Blood Banks Based on Inventory A Peek into China?s Cord Blood Banking Industry Evolving Landscape of Cord Blood Banking Industry Placental Stem Cells and Potential Clinical Applications EXHIBIT 1: Global Cord Blood Banking Market Share Breakdown (%) by Bank Type: 2019 EXHIBIT 2: US Cord Blood Banking Market by Bank Type (in %) for 2019 Changing Business Models for Stem Cell Banking 2. FOCUS ON SELECT PLAYERS Cord Blood Registry (CBR) Systems, Inc. (USA) Cordlife Group Limited (Singapore) Cryo Stemcell Private Limited (India) Cryo-Cell International, Inc. (USA) Cryoviva Biotech Private Limited (India) Global Cord Blood Corporation (China) LifeCell International Pvt. Ltd (India) Smart Cells International Ltd. (UK) StemCyte (USA) Takara Bio Europe AB (Europe) ViaCord (US) Vita34 AG (Germany) 3. MARKET TRENDS & DRIVERS Increasing Investments in Stem Cell-Based Research Widen Prospects for Stem Cell Banking Market EXHIBIT 3: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 Stem Cell Research Policies Impact Funding Volumes Adult Stem Cell Research Gains Traction, Accelerating Research Funding Adult Stem Cells Vs. Embryonic Stem Cells: A Comparison Embryonic Stem Cell Research Bogged Down by Ethical Issues & Technical Hurdles Induced Pluripotent Stem Cell (iPSC) Research: The Latest Vertical Sustained Emphasis on Mesenchymal Stem Cell Research Emergence of Advanced Technologies for Stem Cell Preservation, Storage and Processing Augurs Well for Market Growth Growing Incidence of Major Diseases to Boost the Demand for Stem Cells, Driving Stem Cell Banking EXHIBIT 4: Worldwide Incidence of Cancer (2012, 2018 & 2040): Number of New Cases Diagnosed Table 8: World Cancer Incidence by Cancer Type (2018): Number of New Cancer Cases Reported (in Thousands) for Breast, Cervix uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach and Others Table 9: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others Table 10: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) Ageing Demographics to Drive Demand for Stem Cell Banking Global Aging Population Statistics - Opportunity Indicators Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2017 & 2050) Table 4: Global Aging Population (2017 & 2050): Population of 60+ Individuals in ?000s and as a Percentage of Total Population Table 5: Life Expectancy for Select Countries in Number of Years: 2018 Bone Marrow Stem Cells Market on a Rapid Growth Path, Spurring the Need for Stem Cell Banking Development of Regenerative Medicine Accelerates Demand for Mesenchymal Stem Cell Banking Table 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell Banking Table 1: Global Orthopedic Surgical Procedure Volume (2010-2020) (in Million) Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Stem Cell Banking Rise in the Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion Hematopoietic Stem Cell Storage Dental Mesenchymal Stem Cells: An Evolving Niche Therapeutic Potential of Dental Pulp Stem Cells (DPSCs) in Various Diseases High Operational Costs of Stem Cell Banking - A Key Market Restraint 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 Table 3: World Current & Future Analysis for Placental and Cord Blood Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 4: World 7-Year Perspective for Placental and Cord Blood Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 5: World Current & Future Analysis for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 6: World 7-Year Perspective for Adipose Tissue-Derived Stem Cells (ADSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 7: World Current & Future Analysis for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World 7-Year Perspective for Bone Marrow-Derived Stem Cells (BMSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 9: World Current & Future Analysis for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 10: World 7-Year Perspective for Human Embryo-Derived Stem Cells (HESCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 11: World Current & Future Analysis for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 12: World 7-Year Perspective for Dental Pulp-Derived Stem Cells (DPSCS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 13: World Current & Future Analysis for Other Stem Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World 7-Year Perspective for Other Stem Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 15: World Current & Future Analysis for Sample Preservation and Storage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 16: World 7-Year Perspective for Sample Preservation and Storage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 17: World Current & Future Analysis for Sample Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 18: World 7-Year Perspective for Sample Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 19: World Current & Future Analysis for Sample Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World 7-Year Perspective for Sample Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 21: World Current & Future Analysis for Sample Collection and Transportation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 22: World 7-Year Perspective for Sample Collection and Transportation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 23: World Current & Future Analysis for Personalized Banking Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 24: World 7-Year Perspective for Personalized Banking Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 25: World Current & Future Analysis for Research Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 26: World 7-Year Perspective for Research Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 27: World Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 28: World 7-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 29: USA Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 30: USA 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 31: USA Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: USA 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 33: USA Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 34: USA 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 CANADA Table 35: Canada Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 36: Canada 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 37: Canada Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Canada 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 39: Canada Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 40: Canada 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 JAPAN Table 41: Japan Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 42: Japan 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 43: Japan Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: Japan 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 45: Japan Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 46: Japan 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 CHINA Table 47: China Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 48: China 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 49: China Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: China 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 51: China Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 52: China 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 EUROPE Table 53: Europe Current & Future Analysis for Stem Cell Banking by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 54: Europe 7-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 Table 55: Europe Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 57: Europe Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 58: Europe 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 59: Europe Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 60: Europe 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 FRANCE Table 61: France Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: France 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 63: France Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 64: France 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 65: France Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 66: France 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 GERMANY Table 67: Germany Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 69: Germany Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 70: Germany 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 71: Germany Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 72: Germany 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 ITALY Table 73: Italy Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 75: Italy Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 76: Italy 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 77: Italy Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 78: Italy 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 UNITED KINGDOM Table 79: UK Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: UK 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 81: UK Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 82: UK 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 83: UK Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 84: UK 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 REST OF EUROPE Table 85: Rest of Europe Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Rest of Europe 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 87: Rest of Europe Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 88: Rest of Europe 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 89: Rest of Europe Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 90: Rest of Europe 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 ASIA-PACIFIC Table 91: Asia-Pacific Current & Future Analysis for Stem Cell Banking by Source - Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Asia-Pacific 7-Year Perspective for Stem Cell Banking by Source - Percentage Breakdown of Value Sales for Placental and Cord Blood Stem Cells, Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS) and Other Stem Cell Sources for the Years 2020 & 2027 Table 93: Asia-Pacific Current & Future Analysis for Stem Cell Banking by Service Type - Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 94: Asia-Pacific 7-Year Perspective for Stem Cell Banking by Service Type - Percentage Breakdown of Value Sales for Sample Preservation and Storage, Sample Analysis, Sample Processing and Sample Collection and Transportation for the Years 2020 & 2027 Table 95: Asia-Pacific Current & Future Analysis for Stem Cell Banking by Application - Personalized Banking Applications , Research Applications and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 96: Asia-Pacific 7-Year Perspective for Stem Cell Banking by Application - Percentage Breakdown of Value Sales for Personalized Banking Applications , Research Applications and Clinical Applications for the Years 2020 & 2027 REST OF WORLD Table 97: Rest of World Current & Future Analysis for Stem Cell Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

细胞疗法

100 项与 Swiss Transfusion SRC 相关的药物交易

登录后查看更多信息

100 项与 Swiss Transfusion SRC 相关的转化医学

登录后查看更多信息